Ascelia Pharma: Clear-cut objectives for 2025 - Redeye

Q4 is a reminder that Ascelia ticked some essential boxes during 2024, including completing a successful phase 3 study and securing growth capital for at least the entire 2025. Q4 is also a reminder that 2025 is about ensuring a timely FDA submission by mid-2025, promoting the phase 3 results and advancing ongoing conversations with potential partners ahead of the launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1073622/ascelia-pharma-clear-cut-objectives-for-2025?utm_source=finwire&utm_medium=RSS